AbbVie Inc. ABBV
264.34
(0.78)
(0.29%)
as of 25 Sep
- Market cap
- $467.4B
- P/E
- 74.7×
Follow ABBV
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
AbbVie Inc. (ABBV) P/S ratio
As of 25 September 2026, AbbVie Inc. (ABBV) trades at a P/S ratio of 7.3×. Over the past ten years it has ranged from 2.9× (August 2019) to 7.3× (August 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers General industry median of 3.3× and above the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 6.6× | 18.44% |
| FY2024 | 5.6× | 7.27% |
| FY2023 | 5.2× | 5.01% |
| FY2022 | 5.0× | 16.16% |
| FY2021 | 4.3× | 9.36% |
| FY2020 | 3.9× | (1.07%) |
| FY2019 | 3.9× | (9.12%) |
| FY2018 | 4.3× | (22.08%) |
| FY2017 | 5.6× | 40.98% |
| FY2016 | 3.9× | (6.24%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 6.9× | 12.82% |
| Mar 2026 | 6.1× | (7.28%) |
| Dec 2025 | 6.6× | (3.76%) |
| Sep 2025 | 6.9× | 22.05% |
| 42 more quarters | Free account |
Against its own ten years
Low 2.9×
High 7.3×
Ten-year median
4.5×
Current reading's percentile
100
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PFE Pfizer Inc. compare | 2.6× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| MRK Merck & Co., Inc. compare | 5.5× |
| AMGN Amgen Inc. compare | 5.9× |
| GILD Gilead Sciences, Inc. compare | 6.2× |
| JNJ Johnson & Johnson compare | 6.7× |
| ABBV AbbVie Inc. | 7.3× |
| LLY Eli Lilly and Company compare | 13.3× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on ABBV
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement